Naturally selected CD7 CAR T cell therapy for T-lineage malignancies, CD4+ T cell exhaustion and PD-L1 inhibition in B-ALL, and tPA-induced phosphorylation of occludin in stroke

episode

Blood Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Pretty Little Episode #110 26 min · 25 Sep 2026 · Handsome

Ireland collapse in Kosovo as Israel game looms 13 min · 25 Sep 2026 · Today with David McCullagh

Living Breakthrough-Minded | Joel Osteen 30 min · 25 Sep 2026 · Joel Osteen Podcast

4AM ET 09/25/2026 Newscast 3 min · 25 Sep 2026 · Fox News Hourly Update

The Week: Trump vs the Press, Meta’s AI Win, and the Turning Political Tide 22 min · 25 Sep 2026 · The Prof G Pod with Scott Galloway

Gabrielle Lyon Part 2 1h 1m · 25 Sep 2026 · unPAUSED with Dr. Mary Claire Haver

Report any issue

Source

Recorded28 Jul 2022

Publisherfeeds.transistor.fm ↗

Handlerec:11742076

Show notes

In this week’s episode we review a novel approach to generating autologous CD7-specific CAR T therapy for patients with T-cell malignancies that overcomes a key limitation: target-driven fratricide. We’ll also learn about new research pinpointing a key subset of exhausted CD4+ T cells in B- ALL, which also provides a rationale for combining tyrosine kinase inhibitors and PD-L1 blockers to reverse exhaustion and enhance leukemia clearance. Finally, we’ll discuss studies in a mouse model of acute ischemic stroke, showing that inhibiting phosphorylation of a tight junction protein in endothelial cells reduces risk of intracranial hemorrhage after treatment with recombinant tissue plasminogen activator.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in